Drug resistance in Mexico: Results from the National Survey on Drug-Resistant Tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 514-519

  Bojorquez Chapela, I ^a   Backer C E ^b   Orejel, I ^c   Lopez A ^d   Diaz Quinonez A ^b,e   Hernandez Serrato M I ^f   Balandrano, S ^b   Romero, M ^f   Solís, M M Téllez Rojo ^f   Castellanos, M ^c   Alpuche, C ^f   Hernandez Avila M ^f   Lopez Gatell H ^f  

^a EL COLEGIO DE LA FRONTERA NORTE   (Mexico)

^b Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^c Centro Nacional de Programas Preventivos y Control de Enfermedades   (Mexico)

^d Instituto Nacional de Estadística y Geografía   (Mexico)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Epidemiology; Multidrugresistant tuberculosis; Pulmonary tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SPUTUM SMEAR;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HEALTH SURVEYS; HUMANS; ISONIAZID; MALE; MEXICO; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84875421710     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0167     Document Type: Article

References (18)

1. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 201-1.
2. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB). 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Swizerland: WHO, 201-0.
3. Zazueta-Beltran J S, Muro-Amador S, Flores-Gaxiola A, Llausas-Magaña E, León-Sicarios N, Canizalez-Roman A. High rates of multidrug-resistant Mycobacterium tuberculosis in Sinaloa State, Mexico. J Infect 2007; 54: 411-41-2.
4. Granich R M, Balandrano S, Santaella A J, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med 2000; 160: 639-64-4.
5. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM-006-SSA-1993, para la prevención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federación 27 de septiembre de 2005. México DF, Mexico: SSA, 2005. [Spanish]
6. World Health Organization. Interim recommendations for the surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2007.385. Geneva, Switzerland: WHO, 200-7.
7. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO/CDS/TB/2003.320. WHO/CDS/CSR/RMD/2003.3 Geneva, Switzerland: WHO, 200-3.
8. World Health Organization. Guidance on regulations for the transport of infectious substances. WHO/CDS/CSR/LYO/2005. 22. Geneva, Switzerland: WHO, 200-5.
9. Farga V, Caminero J A. Tuberculosis. 3rd ed. Santiago, Chile: Mediterráneo/La Unión, 2011. [Spanish]
10. Siddiqi S H. BACTEC TB system. Product and procedure manual. Revision B. Towson, MD, USA: Becton Dickinson Diagnostic Instruments System, 198-9.
11. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-187-3.
12. Al-Akhali A, Ohkado A, Fujiki A, et al. Nationwide survey on the prevalence of anti-tuberculosis drug resistance in the Republic of Yemen, 2004. Int J Tuberc Lung Dis 2007; 11: 1328-133-3.
13. Yamada N, Saorith K, Yamakami K, et al. The National Tuberculosis Drug Resistance Survey in Cambodia, 2000-2001. Int J Tuberc Lung Dis 2007; 11: 1321-132-7.
14. Mdivani N, Zangaladze E, Volkova N, et al. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008; 12: 635-64-4.
15. Taylor J P, Suarez L. Prevalence and risk factors of drugresistant tuberculosis along the Mexico-Texas border. Am J Public Health 2000; 90: 271-27-3.
16. Faustini A, Hall A J, Perucci C A. Risk factors for multidrugresistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-16-3.
17. World Health Organization. Anti-tuberculosis drug resistance in the world. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 200-8.
18. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drugresistant tuberculosis by 2015. WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 201-1.